Provided are methods for preventing, treating, suppressing type 1 diabetes, or reversing one or more symptoms of T1D, or delaying the onset of T1D comprising administration to a subject a composition comprising liposomes and insulin intercalated in the bilayer of the liposomes, wherein the bilayer comprises lyso-PS.

Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.

Provided herein are compositions comprising niacin, berberine, one or more of silymarin, silibinin, and Siliphos®, lipoic acid, taurine, and phosphatidylcholine. Such compositions are useful for treating or preventing obesity, metabolic and hepatic and neurodegenerative disorders.

Compositions are provided according to aspects of the present invention that include a hydrogel and a liner, wherein a surface of the hydrogel dissociably-engages a surface of the liner. Compositions are provided according to aspects of the present invention that include a hydrogel and a hydrophobic glue, wherein at least a portion of the gel network of the hydrogel is occupied by the hydrophobic glue. Reverse coaling processes and articles of manufacture made by reverse coating processes are provided according to aspects of the present invention. Compositions are provided according to aspects of the present invention that include a hydrogel and a substrate, wherein: the hydrogel comprises a polymer network; the substrate comprises a surface comprising a polymer network; and the polymer network of the hydrogel and the polymer network of the surface are entangled.

Proposed is a nanoparticle complex containing a nanoparticle that ingestible into a cell, and a lipid-based lipid structure bonded to one portion of an outer surface of the nanoparticle and improving a cellular uptake efficiency of the nanoparticle, wherein the nanoparticle contains a first reactive group, the lipid structure contains a second reactive group chemically bonded to the first reactive group of the nanoparticle, the first reactive group and the second reactive group are chemically bonded to each other, and thus the lipid structure is bonded to the nanoparticle.

The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.

The present disclosure provides liposomal formulations comprising a lipid membrane comprising at least one liposome forming phospholipid and a sterol; and an intraliposomal aqueous compartment encapsulating at least one ATI receptor blocker (ARB) and a pH-dependent ionizable anion; with the liposomes having an effect upon administration to a subject in need of said effect, without causing a reduction in mean blood pressure of said subject of more than 50% as compared to the administration of the same amount of ARB in free form. The liposomes can be for systemic administration, e.g. by injection or for pulmonary administration, e.g. by inhalation

Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Disclosed herein are therapeutic compounds capable of targeting abroad range of tumor cells. The present disclosure is further directed to compositions comprising the therapeutic compounds, methods of manufacturing the therapeutic compounds, and methods of treating cancer comprising administering the therapeutic compounds.

Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.